<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02144389</url>
  </required_header>
  <id_info>
    <org_study_id>2012-1054</org_study_id>
    <nct_id>NCT02144389</nct_id>
  </id_info>
  <brief_title>Arachidonic Acid Treatment Against Schistosomiasis Infection in Children</brief_title>
  <official_title>Effects of Arachidonic Acid Supplementation on Schistosomiasis Mansoni Infection in Egyptian School Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DSM Nutritional Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Liver Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>High Institute of Public Health, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>DSM Nutritional Products, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized Controlled Trial:

      The investigational materials used in this trial were administered to subjects each day by
      trained clinicians.

      Primary Objectives:

        -  assess the effect of dietary supplementation with arachidonic acid on the cure rates for
           Schistosomiasis mansoni with and without concomitant treatment with praziquantel.

        -  assess the safety of dietary supplementation using arachidonic acid in children with
           clinically confirmed schistosomiasis mansoni infection.

      Secondary objective:

        -  to measure changes in total phospholipids in plasma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent egg reduction</measure>
    <time_frame>4 weeks after end of 1 day PZQ treatment</time_frame>
    <description>Stool samples were collected from each child on three consecutive days to determine egg counts per gram of stool.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical and hematological parameters</measure>
    <time_frame>Three days after a 15-day ARA supplementation</time_frame>
    <description>Blood samples were collected using 4 vacutainer tubes. Serum was used to measure enzyme markers of liver and kidney functions. Coagulation tests included prothrombin- and activated thromboplastin times were measured using citrated blood. Complete hematological profiles were obtained using EDTA-anticoagulated blood samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma phospholipids</measure>
    <time_frame>Three days after 15-day ARA supplementation.</time_frame>
    <description>Blood samples (10 ml) were collected 2-3 days before the start of treatment, and 3 days after completion of treatment with ARA or PZQ+ARA for analysis of the phospholipids in plasma.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">335</enrollment>
  <condition>Schistosomiasis</condition>
  <condition>Bilharzia</condition>
  <arm_group>
    <arm_group_label>Praziquantel (PZQ)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single dose of praziquantel (40 mg/kg) was administered orally on day-1 only, and after 7 days, 1 g of corn oil/soybean oil (50%/50%), for 15 consecutive days of school.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arachidonic acid (ARA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single daily dose of 1 g microbial arachidonic acid-rich oil administered orally for 15 consecutive days of school.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PZQ + ARA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of PZQ (40 mg/kg) was administered orally on day-1 only, and after 7 days, followed the next day by 1 g of microbial ARA-rich oil, administered orally as a single dose on 15 consecutive days of school.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Praziquantel (PZQ)</intervention_name>
    <description>40 mg/kg, a single dose, administered orally
1 g of corn/soybean oil (50%/50%), administered orally</description>
    <arm_group_label>Praziquantel (PZQ)</arm_group_label>
    <other_name>Praziquantel (generic)</other_name>
    <other_name>Biltricide</other_name>
    <other_name>trematodicide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Arachidonic acid (ARA)</intervention_name>
    <description>ARA (40% of total fatty acid)</description>
    <arm_group_label>Arachidonic acid (ARA)</arm_group_label>
    <other_name>ARASCO</other_name>
    <other_name>Microbial arachidonic acid-rich oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PZQ+ARA</intervention_name>
    <description>A single dose of PZQ administered seven days in advance of initial treatment with ARA.</description>
    <arm_group_label>PZQ + ARA</arm_group_label>
    <other_name>ARASCO</other_name>
    <other_name>praziquantel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  consent from parent or legal guardian

          -  clinically confirmed schistosomiasis

        Exclusion Criteria:

          -  not infected with schistosomiasis

          -  less than 6 or greater than 15 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rashika El Ridi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sahar Selim, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>National Liver Institute, Menoufiya University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rashida Barakat, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>High Institute of Public Health, Alexandria University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Liver Institute, Menoufiya University,</name>
      <address>
        <city>Shebin El-Kom</city>
        <state>Menoufiya</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tropical Health Department, High Institute of Public Health, Alexandria University</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2014</study_first_submitted>
  <study_first_submitted_qc>May 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2014</study_first_posted>
  <last_update_submitted>May 19, 2014</last_update_submitted>
  <last_update_submitted_qc>May 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arachidonic acid</keyword>
  <keyword>Bilharzia</keyword>
  <keyword>Mansoni</keyword>
  <keyword>Schistosomiasis</keyword>
  <keyword>Polyunsaturated fatty acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schistosomiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Praziquantel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

